Evans, Brian C. http://orcid.org/0000-0001-7450-0620
Fletcher, R. Brock http://orcid.org/0000-0002-3986-9040
Kilchrist, Kameron V. http://orcid.org/0000-0002-2391-9488
Dailing, Eric A. http://orcid.org/0000-0002-2299-7783
Mukalel, Alvin J.
Colazo, Juan M. http://orcid.org/0000-0002-3591-4246
Oliver, Matthew
Cheung-Flynn, Joyce
Brophy, Colleen M.
Tierney, John W.
Isenberg, Jeffrey S.
Hankenson, Kurt D. http://orcid.org/0000-0001-6361-143X
Ghimire, Kedar
Lander, Cynthia
Gersbach, Charles A. http://orcid.org/0000-0003-1478-4013
Duvall, Craig L.
Article History
Received: 27 February 2019
Accepted: 7 October 2019
First Online: 1 November 2019
Competing interests
: Cynthia Lander is the founder, chairman, chief executive officer, and stockholder of Moerae Matrix, Inc., which is conducting clinical trials using the YARA-MK2i peptide. A patent application has been filed for the polyplex delivery technology (PCT/US14/33873). The remaining authors declare no competing interests.